Q-omics provides the consensus-scored GLB1 profile across patient tissues and cancer cell-line models. GLB1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GLB1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GLB1 protein abundance shows 20,125 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where GLB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLB1 survival associations across molecular data types. GLB1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLB1 RNA expression–survival associations across cancer types. High GLB1 expression shows unfavorable associations in MESO, LGG and LIHC, but favorable associations in SCLC, READ and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for GLB1 RNA expression.
This table summarizes GLB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLB1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, BLCA, LIHC, COAD and STAD. The HNSC box plot shows higher GLB1 RNA expression in tumor versus normal tissue (log2 FC = +0.926, t-test p < 0.001).
This table shows molecular features associated with GLB1 in patient tissues and cancer cell lines. In patient samples, GLB1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GLB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
